ESR1 and neoplasm: Part of this evolution may also be explained by the loss in expression of ER and PR in tumor cells and splicing variants as well as altered sensitivity and activation of proliferating pathways (EGFR, PI3K/AKT/mTOR, RAS/Raf/MAPK).2